Form 4: Generation Bio Director Disposes Shares in Merger

Generation Bio Co. director Catherine Stehman-Breen disposed of common stock and options as the company became a wholly-owned subsidiary of XOMA Royalty Corporation following a merger.

Summary

• Catherine Stehman-Breen, a Director of Generation Bio Co. (GBIO), reported changes in beneficial ownership due to a merger.
• Generation Bio Co. was acquired by XOMA Royalty Corporation, becoming its wholly-owned subsidiary, effective February 9, 2026.
• Stehman-Breen disposed of 4,752 shares of Common Stock, which were exchanged for $4.2913 cash per share plus one non-tradeable contingent value right (CVR) per share.
• The CVR has an estimated maximum contingent consideration of $25.01 per CVR.
• Stock options with an exercise price less than the cash amount ($4.2913) were converted into cash (e.g., 3,000 shares at $3.874 exercise price).
• Stock options with an exercise price equal to or greater than the cash amount were automatically cancelled for no consideration (e.g., options for 5,200, 1,500, 1,920, 2,500, and 6,000 shares with exercise prices ranging from $33.2 to $265.9).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event for the reporting person, as it represents the mandatory execution of a pre-determined merger agreement, with some holdings yielding cash and others being cancelled without consideration.

Positives

• Reporting person received cash consideration of $4.2913 per share for common stock.
• Reporting person received one non-tradeable contingent value right (CVR) per share, with an estimated maximum contingent consideration of $25.01.
• In-the-money stock options were converted into cash, providing a payout for those holdings.

Negatives

• Stock options with an exercise price equal to or greater than the cash amount were cancelled for no consideration, resulting in a loss of potential value for those holdings.
• Generation Bio Co. is no longer an independent publicly traded entity.

Risks

• The contingent value right (CVR) is non-tradeable, limiting liquidity.
• The CVR has an 'estimated maximum contingent consideration amount,' implying that the actual payout could be less than $25.01 and is subject to future conditions.

Future Outlook

Generation Bio Co. is now a wholly-owned subsidiary of XOMA Royalty Corporation, meaning its independent operational and financial outlook is subsumed by the parent company. Future value for former shareholders holding CVRs depends on the contingent payments outlined in the CVR agreement.

Industry Context

StockSavvy.ai notes this Form 4 filing reflects the final stages of a corporate acquisition, a common event in the biotechnology and pharmaceutical sectors. Such transactions typically involve the conversion or cancellation of insider equity holdings according to the merger agreement terms, leading to the acquired company becoming a private entity under the acquirer.

Corporate Governance

Stakeholder Impact

• Shareholders: Received $4.2913 cash per share plus one non-tradeable CVR with an estimated maximum value of $25.01.
• Option Holders (In-The-Money): Received cash equal to the difference between the cash amount and the exercise price, multiplied by the number of shares.
• Option Holders (Out-of-The-Money): Options were cancelled for no consideration.

Next Steps

• Contingent payments related to the non-tradeable CVRs will be made in cash in accordance with the terms and conditions of the contingent value rights agreement.

Key Dates

Keywords

Generation Bio, GBIO, XOMA Royalty Corporation, Merger, Acquisition, Form 4, Insider Transaction, Stock Options, Contingent Value Right, CVR